MANGOCEUTICALS, INC. Reports Board & Executive Changes
Ticker: MGRX · Form: 8-K · Filed: Apr 11, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
MANGOCEUTICALS, INC. is shuffling its board and exec pay. Big changes coming?
AI Summary
On April 10, 2025, MANGOCEUTICALS, INC. reported changes in its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific names of departing and newly elected individuals, along with details of their compensation packages, are expected to be provided within the full filing.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or future performance, impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect future company performance and strategy.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing history with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- Texas (location) — State of incorporation
- April 10, 2025 (date) — Date of earliest event reported
FAQ
Who are the specific officers and directors departing MANGOCEUTICALS, INC. as of April 10, 2025?
The filing indicates the departure of certain officers and directors, but the specific names are not listed in this summary section of the 8-K.
Which new directors have been elected to the MANGOCEUTICALS, INC. board?
The filing states that new directors have been elected, but their names are not provided in this initial summary.
What are the key changes in the compensatory arrangements for MANGOCEUTICALS, INC. officers?
The 8-K filing mentions updates to compensatory arrangements for certain officers, but the specific details of these changes are not included in this summary.
What is the primary reason for the reported changes in directors and officers at MANGOCEUTICALS, INC.?
The filing does not explicitly state the reason for the departures and elections, only that these events occurred on or before April 10, 2025.
Where is MANGOCEUTICALS, INC. primarily located?
MANGOCEUTICALS, INC.'s principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 11, 2025 regarding MANGOCEUTICALS, INC. (MGRX).